Department of Psychology, Ludwig Maximilian University Munich, Munich, Germany.
Zurich Center for Neuroeconomics, Department of Economics, University of Zurich, Zürich, Switzerland.
Elife. 2023 Mar 8;12:e83734. doi: 10.7554/eLife.83734.
Theoretical accounts disagree on the role of dopamine in intertemporal choice and assume that dopamine either promotes delay of gratification by increasing the preference for larger rewards or that dopamine reduces patience by enhancing the sensitivity to waiting costs. Here, we reconcile these conflicting accounts by providing empirical support for a novel process model according to which dopamine contributes to two dissociable components of the decision process, evidence accumulation and starting bias. We re-analyzed a previously published data set where intertemporal decisions were made either under the D2 antagonist amisulpride or under placebo by fitting a hierarchical drift diffusion model that distinguishes between dopaminergic effects on the speed of evidence accumulation and the starting point of the accumulation process. Blocking dopaminergic neurotransmission not only strengthened the sensitivity to whether a reward is perceived as worth the delay costs during evidence accumulation (drift rate) but also attenuated the impact of waiting costs on the starting point of the evidence accumulation process (bias). In contrast, re-analyzing data from a D1 agonist study provided no evidence for a causal involvement of D1R activation in intertemporal choices. Taken together, our findings support a novel, process-based account of the role of dopamine for cost-benefit decision making, highlight the potential benefits of process-informed analyses, and advance our understanding of dopaminergic contributions to decision making.
理论观点在多巴胺在跨期选择中的作用上存在分歧,假设多巴胺要么通过增加对更大奖励的偏好来促进延迟满足,要么通过增强对等待成本的敏感性来降低耐心。在这里,我们通过为一个新的过程模型提供实证支持来调和这些相互矛盾的观点,根据该模型,多巴胺有助于决策过程的两个可分离成分,即证据积累和起始偏差。我们重新分析了一个先前发表的数据集合,其中通过拟合一个层次漂移扩散模型来区分多巴胺对证据积累速度和积累过程起点的影响,在这个数据集合中,被试在 D2 拮抗剂安非他酮或安慰剂的作用下做出跨期决策。阻断多巴胺能神经传递不仅增强了对在证据积累过程中(漂移率)感知到的奖励是否值得延迟成本的敏感性,而且减弱了等待成本对证据积累过程起点的影响(偏差)。相比之下,重新分析 D1 激动剂研究的数据并没有为 D1R 激活在跨期选择中的因果关系提供证据。总的来说,我们的发现支持了一种新的、基于过程的多巴胺在成本效益决策中的作用的观点,强调了基于过程的分析的潜在好处,并推进了我们对多巴胺对决策的贡献的理解。